Performance of statistical methods on CHARGE targeted sequencing data

BMC Genetics

L Adrienne Cupples²  Josée Dupuis²  Chuanhua Xing¹ 

[1]Department of Biostatistics, Boston University, Boston, MA, USA

[2]Framingham Heart Study, Framingham, MA, USA

关键词: Burden tests;    Madsen and browning;    Score-Seq;    SKAT;    Power;    Type I error;    Rare variants;    CHARGE targeted sequencing data;    Case-cohort design;   

Others  :  1085529
DOI  :  10.1186/s12863-014-0104-9

 received in 2014-05-28, accepted in 2014-09-22,  发布年份 2014

【 摘 要 】

Background

The CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Sequencing Project is a national, collaborative effort from 3 studies: Framingham Heart Study (FHS), Cardiovascular Health Study (CHS), and Atherosclerosis Risk in Communities (ARIC). It uses a case-cohort design, whereby a random sample of study participants is enriched with participants in extremes of traits. Although statistical methods are available to investigate the role of rare variants, few have evaluated their performance in a case-cohort design.

Results

We evaluate several methods, including the sequence kernel association test (SKAT), Score-Seq, and weighted (Madsen and Browning) and unweighted burden tests. Using genotypes from the CHARGE targeted-sequencing project for FHS (n = 1096), we simulate phenotypes in a large population for 11 correlated traits and then sample individuals to mimic the CHARGE Sequencing study design. We evaluate type I error and power for 77 targeted regions.

Conclusions

We provide some guidelines on the performance of these aggregate-based tests to detect associations with rare variants when applied to case-cohort study designs, using CHARGE targeted sequencing data. Type I error is conservative when we consider variants with minor allele frequency (MAF) < 1%. Power is generally low, although it is relatively larger for Score-Seq. Greater numbers of causal variants and a greater proportion of variance improve the power, but it tends to be lower in the presence of bi-directionality of effects of causal genotypes, especially for Score-Seq.

【 授权许可】

   
2014 Xing et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Xing C, Satten GA, Allen AS: A weighted accumulation test for associating rare genetic variation with quantitative phenotypes. BMC Proc 2011, 5(Suppl 9):S6. BioMed Central Full Text
• [2]Hoffmann TJ, Marini NJ, Witte JS: Comprehensive approach to analyzing rare genetic variants. PLoS One 2010, 5(11):e13584.
• [3]Ahituv N, Kavaslar N, Schackwitz W, Ustaszewska A, Martin J, Hebert S, Doelle H, Ersoy B, Kryukov G, Schmidt S, Yosef N, Ruppin E, Sharan R, Vaisse C, Sunyaev S, Dent R, Cohen J, McPherson R, Pennacchio L: Medical sequencing at the extremes of human body mass. Am J Hum Genet 2007, 80:779-791.
• [4]Azzopardi D, Dallosso AR, Eliason K, Hendrickson BC, Jones N, Rawstorne E, Colley J, Moskvina V, Frye C, Sampson JR: Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. Cancer Res 2008, 68:358-363.
• [5]Brunham LR, Singaraja RR, Hayden MR: Variations on a gene: Rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis. Annu Rev Nutr 2006, 26:105-129.
• [6]Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH: Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004, 305:869-872.
• [7]Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, Grundy SM, Hobbs HH: Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A 2006, 103:1810-1815.
• [8]Ji W, Foo JN, O’Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW, Levy D, Lifton RP: Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008, 40:592-599.
• [9]Nejentsev S, Walker N, Riches D, Egholm M, Todd JA: Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009, 324:387-389.
• [10]Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, Hobbs HH, Cohen JC: Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 2009, 119:70-79.
• [11]Slatter TL, Jones GT, Williams MJ, van Rij AM, McCormick SP: Novel rare mutations and promoter haplotypes in ABCA1 contribute to low-HDL-C levels. Clin Genet 2008, 73:179-184.
• [12]Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A: Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008, 320:539-543.
• [13]Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X: Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet 2011, 89(1):82-93.
• [14]Lin DY, Tang ZZ: A general framework for detecting disease associations with rare variants in sequencing studies. Am J Hum Genet 2011, 89(3):354-367.
• [15]Madsen B, Browning S: A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet 2009, 5(2):e1000384.
• [16]Morris A, Zeggini E: An evaluation of statistical approaches to rare variant analysis in genetic association studies. Genet Epidemiol 2010, 34(2):188-193.
• [17]Ladouceur M, Dastani Z, Aulchenko YS, Greenwood CMT, Richards JB: The empirical power of rare variant association methods: results from Sanger sequencing in 1,998 individuals. PLoS Genet 2012, 8(2):e1002496.
• [18]Wang K, Li M, Hakonarson H: ANNOVAR: Functional annotation of genetic variants from next-generation sequencing data. Nucleic Acids Res 2010, 38:e164.
• [19]Basu S, Pan W: Comparison of statistical tests for disease association with rare variants. Genet Epidemiol 2011, 35(7):606-619. 10.1002/gepi.20609. Epub 2011 Jul 18